Navigation Links
Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharma's Scientific and Medical Advisory Board
Date:5/25/2011

LOS ANGELES, May 25, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Patrick Hwu, M.D., and Mario Sznol, M.D., have joined the Company's recently formed Scientific and Medical Advisory Board (SMAB).

Dr. Hwu is currently on the faculty of the University of Texas MD Anderson Cancer Center in Houston, and serves as chairman of the Center's Department of Melanoma Medical Oncology, Division of Cancer Medicine.

Dr. Sznol is currently on the faculty of Yale University School of Medicine, and is Professor of Medicine (Medical Oncology), and also serves as Vice-Chief Medical Oncology and Co-Director of the Yale Cancer Center Melanoma Program.

"We are pleased that Drs. Hwu and Sznol have joined our new Scientific and Medical Advisory Board, and look forward to their contribution in helping to guide our autologous cell therapy program," said Anthony J. Cataldo, President and Chief Executive Officer.

Drs. Hwu and Sznol join other leading oncologists and cancer researchers on the prestigious Genesis Biopharma SMAB who include: Cassian Yee, M.D., Professor of Medicine at the University of Washington's Fred Hutchinson Cancer Research Center; James Mule, Ph.D., and Jeffrey Weber, M.D., Ph.D., of the H. Lee Moffitt Cancer Center & Research Institute; David DiGiusto, Ph.D., of the City of Hope; and Daniel Powell, Ph.D., from the University of Pennsylvania School of Medicine.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies.  For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
2. Patrick Soon-Shiong, M.D. and Michele B. Chan Join Prestigious List of Recipients of KCET Visionary Award at 10th Gala Honoring Region's Philanthropic Leaders
3. Patrick Soon-Shiong, M.D. and Michele B. Chan Join Prestigious List of Recipients of KCET Visionary Award at 10th Gala Honoring Region's Philanthropic Leaders
4. Healthcare Distribution Management Association Names Patrick Kelly New Senior Vice President, Government Affairs
5. Patrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources
6. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
9. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
10. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
11. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Calif. , March 28, 2017 ... of international life sciences corporation Anpac Bio-Medical ... set a new, international record, processing and reporting ... "Cancer Differentiation Analysis" (CDA) liquid biopsy ... World Nobel Prize Laureate Summit publications, Anpac Bio,s ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... and diminished effectiveness over time. A recent study published in STEM CELLS suggests ... stimulating subventricular zone (SVZ) stem cells to produce more neural cells. , ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: ... to report compelling safety and clinical data from its phase ... 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for ... ... a complete safety profile at 6 months and showed no ...
(Date:3/27/2017)... 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular ... detection of foodborne pathogens,  today announced that Mary Duseau ... 2017 Convention on March 29 at 9:50am ET. The conference ... About Roka Bioscience ... Roka Bioscience is a molecular ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
Breaking Biology News(10 mins):